Dutch Biologic Monitor: Fatigue Among Biologic Recipients Across a Range of Immune-Mediated Inflammatory Diseases

Source: Clinical Impact of New Rheumatoid Arthritis Findings From EULAR 2020*
Download Slideset
June 3-6, 2020; Virtual Meeting
Overall, 7% of adults self-reported biologic-associated fatigue. Compared with patients not reporting fatigue, they were younger and more frequently smoked, were more likely to have Crohn disease, and used infliximab, rituximab, or vedolizumab.
Format: Microsoft PowerPoint (.ppt)
File Size: 205 KB
Released: August 13, 2020

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

Related Content

CCO slides: current best practice for choosing among biologics and other JAK inhibitors for patients with moderate to severe ulcerative colitis

Released: November 13, 2020

Expert video from Clinical Care Options (CCO) on optimal management of inflammatory bowel disease (IBD), including ulcerative colitis, Crohn disease

Uma Mahadevan, MD William Sandborn, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Released: November 13, 2020 Expired: November 12, 2021

Pooled analysis of filgotinib trials in rheumatoid arthritis presented at ACR 2020 finds low incidence of VTE and MACE regardless of dose, by CCO

Released: November 13, 2020

ACR 2020: ARCTIC REWIND on flare risk of TNF inhibitor taper and withdrawal among patients with rheumatoid arthritis (RA) and stable remission, as reported by CCO

Released: November 13, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue